Surgery Partners, Inc.

Surgery Partners, Inc. (SGRY) Market Cap

Surgery Partners, Inc. has a market capitalization of $2.01B.

Price: $15.40

-0.50 (-3.14%)

Market Cap: 2.01B

NASDAQ · time unavailable

CEO: J. Eric Evans

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2015-09-30

Website: https://www.surgerypartners.com

Surgery Partners, Inc. (SGRY) - Company Information

Market Cap: 2.01B|Sector: Healthcare

Company Profile

Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.

Analyst Sentiment

86%
Strong Buy

From 12 Active Polls

1Y Forecast: $19.33

▲ +25.5% Potential Upside

Consensus Target Metrics

Low Bound

$17

Median

$20

High Bound

$21

Average

$19

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$19.33
▲ +25.52% Upside
Low Target
$17.00
10% Risk
Median Target
$20.00
30% Mid
High Target
$21.00
36% Max
Consensus
Buy
14 / 22 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,0141,5301,9652,7472,8233,0072,6724,0682,953
Enterprise Value ($M)5,8605,3765,7506,4156,4516,6536,1067,3656,168
Price to Earnings Ratio (P/E)-26.11-10.64-35.11-30.06-282.11-19.79-6.15-32.24-48.77
Price/Earnings-to-Growth Ratio (PEG)-4.54-43.61-0.50-29.60-7.83
Price to Sales Ratio (P/S)0.601.892.223.343.423.873.095.283.87
Price to Book Ratio (P/B)1.170.911.151.591.611.731.492.141.51
Price to Free Cash Flow Ratio (P/FCF)9.68-355.8521.6943.0548.75-180.0529.9990.4052.82
Enterprise Value to Sales (EV/Sales)6.636.507.817.818.577.069.568.09
Enterprise Value to EBITDA (EV/EBITDA)6.1250.8619.4915.8242.4467.7537.9266.2951.57
Debt to Equity Ratio4.012.392.352.242.222.232.071.861.76

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SURGERY PARTNERS INC (SGRY) — Investment Overview

🧩 Business Model Overview

Surgery Partners operates and manages surgical facilities—primarily ambulatory surgery centers (ASCs) and related specialty surgical capacity—along with a physician services platform that supports perioperative workflows. The operating model is anchored in (1) facility ownership/management, (2) contracted relationships with surgeons and referring clinicians, and (3) standardized clinical and operational processes that drive throughput and outcomes.

The value chain runs from procedure demand (patients and referring clinicians) to the execution of surgery in an efficient setting (facility operations, staffing, and scheduling), with revenue largely determined by payer reimbursement and contracted case volumes. Over time, physician and payer contracting promotes stickiness because facilities and services become embedded in referral pathways and care-delivery routines.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from facility-based procedure reimbursement and related ancillary services, supplemented by management/physician services where applicable. Monetisation is driven by a combination of:

  • Case volume and mix: number and complexity of procedures performed, which influences both pricing and variable cost absorption.
  • Utilization and scheduling efficiency: throughput management affects margins through labor and supply leverage.
  • Payer contracting terms: reimbursement rates and out-of-network vs. contracted mix materially influence net revenue per case.
  • Operational standardization: centralized protocols and economies in purchasing and administration support margin resilience.

Overall economics tend to reflect the ratio of fixed facility costs (rent, staffing base, overhead) to variable per-case costs (supplies, anesthesia/professional support where contracted, and procedure-specific materials). As utilization rises or mix shifts toward higher-acuity or higher-reimbursing services, margin expands; conversely, reimbursement pressure or volume softness compresses results.

🧠 Competitive Advantages & Market Positioning

Surgery Partners’ competitive position is best characterized as a combination of high barriers to entry and an integrated ecosystem that improves switching costs for physicians and care pathways.

Moat Thesis: High Barriers to Entry + Integrated Care Pathways

  • Regulatory and operational barriers: building or acquiring capacity requires regulatory approvals, accreditation/credentialing, clinical compliance, and time to operationalize a new site to stable utilization.
  • Physician and referral pathway embeddedness: surgeons and referring clinicians face practical switching frictions once referral habits, staffing models, case scheduling, and payer contracting are established at a given site.
  • Scale-driven cost advantages: consolidated procurement, centralized administration, and standardized clinical operations can lower per-case overhead and improve labor productivity relative to smaller operators.
  • Quality and throughput execution: consistent operational performance supports contracts, referral relationships, and payer negotiation positioning.

Competitive Benchmarking

  • USPI (Optum Ambulatory Services): Large-scale ambulatory operator with broad footprint; competes on scale and contracting leverage. Surgery Partners’ positioning emphasizes surgical facility operations paired with physician services capabilities.
  • Surgical Care Affiliates (SCA): Another focused ASC operator. Competition centers on site-specific demand generation and contracting quality; Surgery Partners competes through operational integration and standardized execution within surgical-focused sites.
  • HCA Healthcare (ambulatory and specialty capacity): Broader healthcare operator with scale and an integrated system approach. Surgery Partners’ focus is narrower and more surgery-centric, aiming for efficient delivery and physician-aligned care pathways rather than diversified system models.

🚀 Multi-Year Growth Drivers

Growth drivers are primarily secular and capacity-based, supported by demographic and care-delivery trends:

  • Shift from inpatient to outpatient surgery: ASCs and specialty surgical sites benefit as payers and patients move procedures to lower-cost outpatient settings when clinically appropriate.
  • Procedure growth from aging demographics: Increased prevalence of conditions requiring elective and semi-elective surgical interventions supports baseline demand.
  • Capacity expansion and site-level rollouts: Opening new sites or expanding existing ones supports multi-year volume growth as utilization ramps.
  • Value-based and quality-linked contracting dynamics: Operators with strong operational consistency can improve payer negotiations over time, particularly where quality metrics and efficiency matter.
  • Physician services support: Enhanced perioperative coordination can strengthen referral relationships and stabilize volumes in competitive local markets.

Over a 5–10 year horizon, the sector’s opportunity is largely tied to ambulatory substitution and the continued need for operationally capable providers to meet demand growth while managing reimbursement and cost inflation.

⚠ Risk Factors to Monitor

  • Payer reimbursement pressure: Changes in Medicare/Medicaid reimbursement policies, commercial fee schedules, and contract renegotiations can compress net revenue per case.
  • Regulatory and compliance risk: ASC and hospital outpatient rules, coverage policies, and documentation requirements can alter economics or increase operating costs.
  • Utilization volatility: Case volume is sensitive to procedure volumes, local referral patterns, and staffing availability. Underutilization can rapidly deteriorate margins due to fixed facility overhead.
  • Labor and supply cost inflation: Staffing costs, anesthesia coverage, and clinical supply costs can outpace reimbursement growth.
  • Site concentration and competitive dynamics: Local market entrants, physician group changes, or payer steering strategies can affect demand and pricing at specific sites.
  • Capital intensity of expansion and M&A execution: Growth often requires development/integration capital, and returns depend on ramp execution, contract acquisition, and operating discipline.

📊 Valuation & Market View

Equity valuation for ambulatory and specialty care operators commonly reflects an EV/EBITDA-style framework, adjusted for operating margin durability, utilization trends, and capital intensity. Market participants typically focus on:

  • Margin quality: sustainability of operating margins through utilization swings and reimbursement cycles.
  • Volume and mix stability: sensitivity to payer mix, procedure mix, and site-level throughput.
  • Growth path credibility: ability to open/expand facilities and ramp to stable utilization without cost overruns.
  • Leverage and refinancing risk: capacity to manage debt and fund growth while maintaining covenant flexibility.
  • Integration track record: disciplined acquisition/roll-up execution and retention of physician and payer relationships.

Given the balance of facility fixed costs and procedure-driven revenue, valuation tends to reward operators that demonstrate consistent execution and resilient contracted economics.

🔍 Investment Takeaway

Surgery Partners’ long-term investment case rests on the structural shift toward outpatient surgery and on hard-to-replicate operational advantages: regulatory and execution barriers, physician/referral pathway embeddedness, and scale-driven cost efficiencies. In a market where reimbursement and utilization drive earnings, the company’s core differentiation lies in integrating facility operations with physician services to sustain throughput and contracting strength through changing care-delivery economics.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SGRY.

gurufocus.com2026-07-31

Is Surgery Partners Inc (SGRY) a Bargain After 3.1% Drop? GF Value Says Undervalued

On July 31, 2026, Surgery Partners Inc (SGRY) shares fell 3.1% to a current price of $15.38. This decline comes amid a 52-week trading range of $11.41 to $24.10

zacks.com2026-07-30

Strength Seen in Surgery Partners (SGRY): Can Its 5.3% Jump Turn into More Strength?

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

benzinga.com2026-07-24

Surgery Partners Monetizes Idaho Assets As It Chases Faster Growth

Surgery Partners, Inc. (NASDAQ:SGRY) stock is trading higher on Friday as the company announced a significant transaction involving the sale of its ownership interests in Idaho Falls facilities to Intermountain Health.

globenewswire.com2026-07-24

Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction

BRENTWOOD, Tenn., July 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced it, along with its existing partner Intermountain Health, has placed into escrow signature pages to definitive agreements, pursuant to which Surgery Partners would sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health.

zacks.com2026-07-08

Fast-paced Momentum Stock Surgery Partners (SGRY) Is Still Trading at a Bargain

Surgery Partners (SGRY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

zacks.com2026-06-22

Why Fast-paced Mover Surgery Partners (SGRY) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Surgery Partners (SGRY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

zacks.com2026-06-18

Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

fool.com2026-06-10

Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?

Surgery Partners operates a massive nationwide network of outpatient surgical facilities and hospitals. Viemed Healthcare is a high-growth specialist focusing on home-based respiratory care and disease management.

seekingalpha.com2026-05-05

Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript

Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript

zacks.com2026-05-05

Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates

Surgery Partners (SGRY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago.

globenewswire.com2026-05-05

Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance

BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026.

globenewswire.com2026-05-05

Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance

BRENTWOOD, Tenn. , May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ: SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 4.

zacks.com2026-04-22

AUNA vs. SGRY: Which Hospital Stock Looks More Attractive Now?

Auna S.A. gains from Peru growth, stabilizing Mexico and Colombia cash flow focus, while Surgery Partners faces earnings cuts and headwinds.

globenewswire.com2026-04-17

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2026 results before the market opens on Tuesday, May 5, 2026, to be followed by a conference call at 8:30 a.m. (Eastern Time).

defenseworld.net2026-04-13

Reviewing Progyny (NASDAQ:PGNY) & Surgery Partners (NASDAQ:SGRY)

Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SGRY reported Q1’26 revenue of $810.9M and net income of -$35.9M (EPS -$0.28). Revenue was -8.4% QoQ (from $885.0M in Q4’25) and +4.5% YoY (from $776.0M in Q1’25). Net income remained negative and deteriorated QoQ: -$35.9M vs -$15.0M in Q4’25 (and vs -$37.7M in Q1’25). Profitability is mixed: gross margin improved to ~19.8% from 20.4% QoQ (and from 20.9% YoY), while operating margin slipped to 8.1% from 12.5% QoQ but is still above Q1’25’s ~8.0%. Cash flow quality weakened. Operating cash flow was $11.7M in Q1’26, down sharply from $103.4M in Q4’25, and free cash flow was slightly negative (-$16K). The company’s balance sheet shows reduced leverage vs Q4’25: total assets eased to $8.0B and net debt fell to ~$190M (vs ~$3.8B in Q4’25), with equity at ~$2.1B (vs $3.5B in Q4’25) suggesting a notable classification/statement shift. Total shareholder returns are pressured by price momentum: the stock is down -33.6% over 1Y and shows no dividend/buyback support in the provided data. Analyst valuation context (consensus target ~$18.6 vs ~$14) implies potential upside, but execution risk remains elevated given persistent net losses."

Revenue Growth

Neutral

Revenue declined -8.4% QoQ to $810.9M but rose +4.5% YoY vs $776.0M, indicating modest underlying growth with near-term softness.

Profitability

Neutral

Net income remains negative (-$35.9M). Operating margin contracted QoQ (8.1% vs 12.5%) and net margin is worse than Q4’25 (-4.4% vs -1.7%). EPS stayed negative (-$0.28).

Cash Flow Quality

Neutral

Operating cash flow fell to $11.7M from $103.4M QoQ. Free cash flow is essentially flat/slightly negative (-$0.02M), consistent with weaker cash conversion in the quarter.

Leverage & Balance Sheet

Caution

Balance sheet shows reduced net debt (~$190M) and lower total assets (~$8.0B), but equity also fell materially vs Q4’25, suggesting structural or accounting shifts; still, liquidity via cash (~$182M) is present.

Shareholder Returns

Neutral

1Y price change is -33.6% (no positive momentum). No dividend payments are shown, and no buybacks are reported in the quarter, limiting shareholder yield.

Analyst Sentiment & Valuation

Caution

Consensus target of $18.6 vs current price ~$14 suggests upside, but the company’s ongoing net losses and volatile cash flows temper sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What? Surgery Partners delivered Q1 2026 results roughly in line with internal expectations: ~$811M net revenue and ~$102M adjusted EBITDA (12.6% margin). Growth was held back by temporary weather-related case deferrals (~40 bps headwind), while high-acuity momentum continued (ASC total joints +14.6%) and robotics adoption (73 robots) supported the shift. Margin execution improved on supply and SWB ratios (27.2% and 30.5%), but management flagged near-term cost pressures tied to reestablishing incentive compensation and new provider tax burdens. Interest expense rose ~ $7M YoY after interest rate swap expiration, though Q2 should benefit from the swap unwind ending. The company reiterated FY2026 guidance (revenue $3.35B–$3.45B; adjusted EBITDA ≥$530M) and emphasized free cash flow improvement via facility-level working capital discipline (DSO ~66 days). Portfolio optimization discussions remain on track for a mid-2026 potential announcement.

AI IconGrowth Catalysts

  • Total joints performed in ASCs grew 14.6% YoY, supported by expanding MSK capacity and surgical robotics (73 robots in portfolio).
  • Physician recruiting of ~140 physicians in Q1 concentrated in orthopedics, ophthalmology, GI and other priority specialties to accelerate volume/acuity ramp.
  • De novo development: 1 new de novo opened in Q1; total openings 9 over trailing 12 months, MSK-heavy to drive higher-acuity case mix.

Business Development

  • Advanced discussions on one portfolio optimization opportunity in a larger surgical hospital market; management targeted announcement in mid-2026.
  • Ongoing disciplined M&A pipeline targeting annual capital deployment of ~$200 million; Q1 acquisitions deployed ~$4 million (estimated ~$7 million of revenue contribution in 2026).

AI IconFinancial Highlights

  • Net revenue ~$811 million; same-facility revenue growth 4.4% (total same-facility case growth 0.6% plus acuity/rate components).
  • Adjusted EBITDA ~$102 million; adjusted EBITDA margin 12.6% (in line with expectations for a seasonally lower Q1).
  • Weather-related disruption drove estimated ~40 bps headwind to growth in higher-volume, lower-acuity markets early in the quarter (GI and eyes mentioned).
  • Expense ratios: supply expense 27.2% of net revenue; SWB expense 30.5% of revenue (both modestly improved YoY). Other operating expenses 7.3% of revenue higher YoY due to provider taxes.
  • Tax/tariff and incentive-comp impacts: management referenced reestablishing incentive compensation, increased provider taxes, and tariff pressures as partially offset by cost controls.
  • Interest expense increased ~$7 million YoY due to higher rates after expiration of an interest rate swap (partially offset by SOFR+250 bps credit facility base rate reductions in 2025 and improved working capital).
  • Guidance: FY2026 revenue reiterated at $3.35B–$3.45B and adjusted EBITDA guidance at at least $530 million; Q2 assumes revenue 24%–24.5% of annual target and adjusted EBITDA 23%–23.5%.

AI IconCapital Funding

  • Share repurchase: no repurchases in Q1; repurchase program will be evaluated opportunistically.
  • Capital deployed: ~$4 million on acquisitions in Q1; ~$9 million maintenance capex in Q1.
  • Physician partner distributions: $58 million in Q1.
  • Leverage: net leverage under credit agreement ~4.3x (flat vs Q4); GAAP net debt/adjusted EBITDA ~5.1x.

AI IconStrategy & Ops

  • Cost management focus after Q4: improving Medicare case profitability via lower labor and supply costs as % of net revenue and continued SWB/supply efficiency work.
  • Planned normalization impacts: reestablishing bonus expected to show more meaningfully in Q2 and more significant pressure in Q3; provider tax pressure to appear in other operating expenses.
  • Working capital execution: DSO ~66 days (flat vs Q4 and prior-year Q1); management targets facility-level working capital discipline as the primary free cash flow lever.

AI IconMarket Outlook

  • Management expects FY2026 objectives to be met/exceeded; M&A impact is not included in FY2026 guidance.
  • Timing: portfolio optimization process still targeted for a mid-2026 announcement; Investor Day planned later in 2026 tied to meaningful portfolio optimization progress.

AI IconRisks & Headwinds

  • Weather-driven deferrals in early Q1 (higher-volume, lower-acuity GI/eyes) created an estimated ~40 bps growth headwind and limited same-facility case growth (0.6%).
  • Payer mix pressure in Q1 moderated from 2H25 but still present; management emphasized Medicare case profitability and commercial market share recovery actions.
  • Provider taxes and tariff pressures: provider tax exposure introduced in 2 new states (title hospital, limited Medicaid) plus a Medicaid-related 4% rate reduction in the one state with Medicaid exposure; these created full-year adjusted earnings pressure estimated at ~$8 million.
  • Seasonality and cost normalization: reestablishing incentive compensation and other provider-tax-related items expected to pressure SWB/other expenses sequentially.

Q&A: Analyst Interest

  • Weather deferrals and quarterly case growth: Management quantified the weather headwind as ~40 bps, concentrated in high-volume lower-acuity GI and eyes, and clarified that lost cases don’t fully “return,” though some timing normalization should occur. They guided that rate will face sequential pressure in Q2 because it’s about normalization, not full case recovery.
  • Provider taxes and P&L flow-through: Management explained provider taxes as new state exposure plus a ~4% Medicaid rate reduction in the one Medicaid-exposed state, estimating ~$8 million full-year adjusted earnings impact. They said quarter impact is partially front-loaded because Medicaid affects three quarters, with the remainder split between revenue and other operating expenses.
  • Cash flow/working capital dynamics and timing: Management said first-quarter cash flow improved largely from timing and partial offsets, while interest-swap termination effects should stop starting in Q2. They emphasized embedding facility-level working capital discipline, citing DSO at ~66 days, and expected a working-capital “unlock” to improve over the year because physician partners benefit from better collections/distributions.

Sentiment: MIXED

Note: This summary was synthesized by AI from the SGRY Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SGRY.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (SGRY)

© 2026 Stock Market Info — Surgery Partners, Inc. (SGRY) Financial Profile